PubMedCrossRef
31. Dias RC, Marangoni DV, Riley LW, Moreira BM: Identification of uropathogenic Dasatinib in vitro Escherichia coli clonal group A (CgA) in hospitalised patients. Memorias do Instituto Oswaldo Cruz 2009,104(5):787–789.PubMedCrossRef 32. Johnson JR, Murray AC, Kuskowski MA, Schubert S, Prere MF, Picard B, Colodner R, Raz R: Distribution and characteristics of Escherichia coli clonal group A. Emerg Infect Dis 2005,11(1):141–145.PubMedCrossRef 33. Manges AR, Johnson JR, Foxman B, O’Bryan TT, Fullerton KE, Riley LW: Widespread distribution of urinary tract infections caused by a multidrug-resistant Escherichia coli clonal group. N Eng J Med 2001,345(14):1007–1013.CrossRef 34. Prats G, Navarro F, Mirelis B, Dalmau D, Margall N, Coll P, Stell A, Johnson JR: VX-809 chemical structure Escherichia coli serotype O15:K52:H1 as a uropathogenic clone. J Clin Microbiol 2000,38(1):201–209.PubMed 35. https://www.selleckchem.com/products/Verteporfin(Visudyne).html Mihaila L, Wyplosz B, Clermont O, Garry L, Hipeaux MC, Vittecoq D, Dussaix E, Denamur E, Branger C: Probable intrafamily transmission of a highly virulent CTX-M-3-producing Escherichia coli belonging to the emerging phylogenetic subgroup D2 O102-ST405 clone. J Antimicrob Chemother 2010,65(7):1537–1539.PubMedCrossRef
36. Clermont O, Lavollay M, Vimont S, Deschamps C, Forestier C, Branger C, Denamur E, Arlet G: The CTX-M-15-producing Escherichia coli diffusing clone belongs to a highly virulent B2 phylogenetic subgroup. J Antimicrob Chemother 2008,61(5):1024–1028.PubMedCrossRef Competing interests The authors declare that they have no competing interests. Authors’ contribution AN was responsible for study conception Fossariinae and design, data acquisition and analysis and drafted the manuscript. LP participated in the conception and design, analysis of data and preparation of the manuscript. CV, JP and CM contributed with data acquisition and analysis. TC and GD were implicated in data analysis and preparation of the manuscript. All authors read and approved the final manuscript.”
“Background Chlamydia
trachomatis is a Gram-negative obligate intracellular bacterium that is a leading cause of preventable blindness and sexually transmitted diseases worldwide [1]. Much of the biology of infection and disease remains unclear in this system, owing largely to the lack of a routine genetic system for these organisms. While many aspects of these challenges have recently been overcome [2, 3], the use of genetic transformation in this system is just beginning to be exploited. One aspect of chlamydial biology that is poorly understood involves the mechanism of lateral gene transfer among chlamydial strains both in the laboratory and, most likely, in patients. Coinfection of host cells in vitro with chlamydial isolates encoding different drug resistance markers lead to generation of dual resistant recombinant progeny [4, 5].